The global Cluster Headache Market size is predicted to be $437.5 Million in 2028. It is expected to grow at a an annual rate of 4.0 percent CAGR over the forecast timeframe -- Yahoo Finance


Cluster headaches are the most frequent among the most common trigeminal autonomic headache types. These headaches can occur once every two days or eight times a day, similar to other trigeminal autonomic cerephalgias.

New York, March 22, 2023 (GLOBE NEWSWIRE) — announces the release of the report “Global Cluster Headache Market Size, Share & Industry Trends Analysis Report By Distribution channel, By Type, By Drug Class, By Regional Outlook and Forecast, 2022 – 2028” –

These occur at the same time during the day typically in the evening. The majority of patients suffer from attacks every day for a period of weeks or months, and then they experience a remission for months or even years. Cluster headaches are an intermittent unilateral headache.

Based on the length of time the cluster headache lasts it can be classified chronic or episodic. The chronic cluster headache can last for more than a full year without any remission, or less than two weeks. Cluster headaches begin suddenly and without prior discomfort. On the other part of the forehead the pain is intense , often described as stinging burning, burning, or piercing. It’s usually felt close to the temple, eye or cheek.

Each strike typically targets the same area. Due to the intensity of the pain is in an attack, people often experience agitation and restlessness and can respond by shaking or moving their heads. Although the exact cause for cluster headaches is not known but they have been linked with hypothalamus activity which is a brain area. Smokers are thought to be more likely to develop cluster headaches.

It is possible to have a genetic relationship between people with cluster headaches and relatives of those who are affected. An episode of cluster headaches can sometimes be caused by drinking drinks or inhaling strong smells such as perfume, paint or gasoline. In the time of no symptoms (remission) and remission, headaches can disappear for months, weeks, or even years , before they return.

COVID-19 Impact Analysis

Headaches caused by COVID-19 are an indication of widespread viral infection. headaches do not help diagnose or predict the outcome for COVID-19-related infection. Headaches are a symptom of COVID-19-related infection, and often coexists with fever and can even depend on it. Also, chronic COVID-19 headaches can manifest as a principal headache that has begun to get worse or, more specifically the case, as an ongoing (intermittent or even daily) headache that develops with the acute infection or following an extended period of. So, the rising incidence of headaches in people who are pandemic-infected is predicted to fuel the expansion of market.

Market Growth Factors

Frequency of cluster headaches increases

The patterns of cluster headaches indicate the hypothalamus, the body’s circadian rhythm, as a possible contraindicating factor. Contrary to migraines and tension headaches the cluster headache usually not caused due to triggers such as specific foods, hormonal fluctuations, or stress. But, alcohol consumption can quickly trigger a split headache when the cluster phase begins. The use of drugs such as the prescription drug nitroglycerin to treat heart ailments could be a reason. The increasing number of people suffering from cluster headaches because of changing lifestyles and consumption of alcohol or certain drugs can boost the growth of the market.

Improved research in the field of medicine and the treatment options available

Natural chemical compounds and their structural analogs have profoundly influenced the field of pharmacology. Recent advances in science and technology that include improved analytical tools including genome mining, engineering techniques, as well as advancements in microbial cultures are solving current issues and generating new possibilities. To fight antimicrobial resistance this has rekindled the interest in natural substances as drugs lead. Natural compounds as well as the increase in pharmaceutical-based R&D will increase the efficacy of the medication for cluster headaches that will lead to market growth.

Market Restrictive Factors

A lack of knowledge about the condition

Cluster headaches do not have a definitive cure. The other treatments focus on decreasing the intensity of pain, reducing the duration of headache, and preventing attacks. Since they require fast-acting medicines and the pain can occur abruptly and then disappear quickly in a flash, cluster headaches are difficult to recognize and manage. The exact cause of these headaches is not known. The cause of cluster headaches do not require any tests. Doctors usually determine the cause by examining the symptoms of a patient and their history . Typically, they keep a headache diary with a list or symptoms that may be useful.

The Drug Class Outlook

Based on class of drugs the market for cluster headaches is divided into ergot derivatives and calcium channel blockers triptans, and more. Triptans dominated the market for cluster headaches, with the largest share of revenue in 2021. This is due to them being a group, or class of drugs that could reduce the frequency of migraine. They work to reduce symptoms by reducing the size of blood vessels in the brain that are caused from migraine-related attacks. Additionally, they come in a variety of doses. Based on the signs the doctor might recommend a different dose such as the doctor may suggest a nasal spray rather than tablets to take in the event of nausea and vomiting, in addition to migraine.

Distribution Channel Outlook

Based on distribution channels the market for cluster headaches is segmented into pharmacies for hospitals as well as drug stores and retail pharmacies, and other. The retail pharmacies and drug stores pharmacies segment accounted for the most percent of the revenue in the market for cluster headaches in 2021. This is due to an increase in the preferring retail pharmacies that offer guidance about the use of medications and their effects throughout treatment. They provide excellent customer service, reasonable costs, and a wide selection of general health and home-based products. Pharmacists in the area can also provide individual consultations and advice immediately.

Type Outlook

The market for cluster headaches is classified as chronic and episodic. Chronic segment had the largest share of revenue in the market for cluster headaches in 2021. This is because most people who suffer from the cluster headaches suffer from chronic forms. Chronic cluster headaches may develop from an periodic form or may occur from the beginning and drive the growth of the segment. Similar to cluster headaches chronic paroxysmal Hemicrania (CPH) is a condition that has less long-lasting with more frequent symptoms which further expands the size of the segment.

Regional Perspective

Regionally, the market for cluster headaches is studied over North America, Europe, Asia Pacific, and LAMEA. It is the North America region registered the largest share of revenue of the market for cluster headaches in 2021. This increase is due to the increasing number of cases of cluster headache throughout the region. There is also an increase in the number of major companies that offer innovative treatments and a better infrastructure for healthcare. With the booming development of a modern healthcare system, and the advancement of cutting-edge technology that can detect illnesses this market is predicted to expand over the forecast time.

The market research report provides the analysis of major stakeholders in the market. The companies that are profiled in the report are Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grunenthal GmbH as well as Arrotex Pharmaceuticals Pty Limited.

Scope of the Study

Market Segments that are covered by the Report:

By distribution channel

* Drug Stores & Retail Pharmacies

* Hospital Pharmacies

* Other

By Type

* Episodic

* Chronic

By the class of drugs

* Tritans

* Calcium Channel Blockers

* Ergot Derivatives

* Other

By Geography

* North America


O Canada

O Mexico

The North America, the Rest North America

* Europe

Germany Germany


O France

O Russia

O Spain

o Italy

o The Rest of Europe

* Asia Pacific

O China

O Japan

O India

O South Korea

o Singapore

O Malaysia

o The Rest of Asia Pacific


o Brazil

O Argentina


o Saudi Arabia

O South Africa

o Nigeria

o The Rest of LAMEA

Companies Profiled

* Dr. Reddy’s Laboratories Ltd.

* Novartis AG

* Sun Pharmaceutical Industries Ltd.

* Teva Pharmaceutical Industries Ltd.

* GlaxoSmithKline PLC (GSK)

* Pfizer, Inc.

* Fresenius SE & Co. KGaA

* Eli Lilly And Company

* Grunenthal GmbH

* Arrotex Pharmaceuticals Pty Ltd

Unique Offerings

* Exhaustive coverage

* The most Tables and charts on the market

* Subscription-based model available

* We guarantee the best price.

* Assured post-sales research support , with 10% customization at no cost

Read the full report:

About Reportlinker

ReportLinker is a prestigious market research software. ReportLinker assembles and organizes the latest data from the industry so you have every market analysis information you require – immediately, all in one location.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001